XOMA (XOMA) Debuts IL-2 Monoclonal Antibody Program at SIC Annual Meeting
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/16/2024
- Stocks close lower as Middle East tensions, Treasury yields weigh
- Apple’s iPhone shipments dip 10% in Q1 as Samsung reclaims the top spot
- Tesla (TSLA) to cut over 10% global staff - Electrek
- Aluminum, Nickel, Copper: LME ban on Russian metal creates buying opportunity?
- Informatica (INFA) jumps as Salesforce (CRM) reportedly eyes new mega takeover
- Trump Media & Technology Group (DJT) Files S-1
- Tesla (TSLA) Senior VP Drew Baglino Is Said To Leave The Company - Bloomberg
- General Motors (GM) Said to be Moving Detroit HQ to Dan Gilbert's Hudson Tower - Bloomberg
- The Israeli Air Force Has Completed Its Preparation For An Imminent Attack Against Iran - Reuters
- Biohaven Pharma (BHVN) presents update on degrader platform and summary of progress to date in Phase 1 single ascending dose study for BHV-1300
- After-hours movers: Tesla, Gildan Activewear, Macatawa Bank, and more
- Midday movers: Goldman Sachs and Meta Platforms rise; Apple and Tesla fall
- Nike, Alpine Immune Sciences rise premarket; CarMax, Robinhood and Regeneron fall
- After-hours movers: Alpine Immune Sciences, Costco, and more
- Midday movers: Delta, Taiwan Semiconductor rise; Hexcel falls
New XOMA Antibodies Unveiled at The Society for Immunotherapy of Cancer 31st Annual Meeting
November 8, 2016 9:00 AM ESTPreclinical Data from XOMAs Novel Anti-IL-2 Immuno-oncology Monoclonal Antibodies Program to be Presented at SITCAdvancing Unique Functional Antibody Antagonists Targeting the Parathyroid Hormone Receptor 1 (PTH1R)Plan to Out-license IL-2 and PTH1R Programs to Fund Endocrine Efforts
BERKELEY, Calif., Nov. 08, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a leader in the discovery and development of therapeutic antibodies, today unveiled its interleukin-2 (IL-2) monoclonal antibody program, a series of novel agents from its scientific discovery research unit, and announced the advancement of its parathyroid hormone receptor 1 (PTH1R)... More
